Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nucleoside polymers show early promise in HBV

Key clinical point: For chronic hepatitis B virus infection, triple-combination therapy with a nucleic acid polymer, tenofovir disoproxil fumarate, and pegylated interferon alfa-2a was tolerable and led to long-term functional cures.

Major finding: At 24-48 weeks after the end of treatment, 78% of patients maintained virologic control and 39% maintained functional cures (HB serum Ag < 0.05 IU per mL, undetectable HBV DNA, and normal ALT).

Study details: Open-label, phase 2 study of 40 adults with chronic HBV infection who tested negative for HBeAg.

Disclosures: Replicor provided funding. Dr. Bazinet and the senior investigator reported that they are employees and shareholders of Replicor and have invented patents that Replicor holds. One coinvestigator reported that Replicor compensated his institution. The remaining 11 coinvestigators reported having no relevant disclosures.

Citation:

Bazinet M et al. Gastroenterology. 2020 Mar 5. doi: 10.1053/j.gastro.2020.02.058.